Abrocitinib for eczema in young children
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is aged 2 to under 6 years.
- They have had eczema for at least 1 year and it is now moderate to severe.
- Their eczema covers at least 10% of their body and they have an itch score of at least 4 out of 10.
- For children outside the US: creams or other topical treatments have not worked after at least 4 weeks, or they needed a stronger medicine by mouth or injection.
- For children in the US: eczema is not controlled with at least one stronger medicine (like dupilumab or oral steroids), or using these medicines is not recommended.
- Your child weighs at least 10 kg (about 22 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
This study looks at how well abrocitinib (a daily pill) works for people with moderate to severe eczema who have already tried biologic medicines and didn't get enough relief. It aims to see if this treatment can help you better manage your eczema.
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
This study tests whether gradually lowering the dose of abrocitinib can keep your eczema under control while reducing side effects. It is for people with moderate-to-severe eczema who have already been on abrocitinib 200 mg daily for at least 3 months and whose skin is currently well controlled.
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.